ISPOR EU

CBPartners will be presenting at the virtual ISPOR Europe 2020 conference – our schedule is outlined below:

IP14: THE SAR-2-COV VACCINE: WHAT DOES AN OPTIMAL VACCINATION STRATEGY LOOK LIKE?

CBPartners’ issue panel will bring together stakeholders from public health bodies and industry to discuss the optimal SAR-2-COV vaccination strategy approach for global public health systems.

MODERATOR: Bami Oshinowo, MSc, Principal and EU Center of Excellence Lead, CBPartners

PANELISTS: Mark Joinnides, MSE, Global Sales Director, COVAXX; Hernan Rosenberg, PhD, Professor of Public Health University of Chile & Universidad de la Frontera

LOCATION: Breakout Room 5

DATE: NOV 19, 2020

TIME: 14:30 – 15:30 (CET)

Research Posters:

• [PCN233] COMMUNICATING VALUE WITH TUMOR-AGNOSTIC THERAPIES
  • https://bit.ly/3p24C9s
• [PNS103] HARNESSING THE POWER OF REAL-WORLD EVIDENCE REGISTRIES
  • https://bit.ly/3p1sdY3
• [PNS189] DEMONSTRATING PAYER VALUE FOR ADJUVANT, NEOADJUVANT, AND CONSOLIDATION THERAPIES
  • https://bit.ly/3mYXNDM
• [PCN205] COST CONTAINMENT IN THE NETHERLANDS: LOCK IT DOWN
  • https://bit.ly/32m8clk
• [PMH36] SCHIZOPHRENIA AND HTA DECISION MAKING
  • https://bit.ly/2U1u80w
• [PCN231] ASSESSING EU HTA TRENDS FOR PD-(L)1S OVER THE YEARS
  • https://bit.ly/3mVz17G
• [PNS164] PAYER ASSESSMENTS OF CELL AND GENE THERAPIES: WHEN IS A DRUG NOT A DRUG?
  • https://bit.ly/3p1riXB
• [PNS72] FROM VOLUME-TO-VALUE IN LATAM – A 6-STEP PROCESS
  • https://bit.ly/3lpXK3H